Summary: Vitamin D and Magnesium both treat shingles
- Shingles worse with low vitamin D, low UV, high latitude, and winter
- Treating shingles with Vitamin D or UV lowers the pain
- Treating shingles with Vitamin D almost eliminates risk of recurrence
- Vitamin D has even been patented to help with shingles
A patent is always a good sign that it probably works
Table of contents
- See also VitaminDWiki
- See on the web
- Hypothesis- Shingles associated with low vitamin D – Oct 2015
- The Varicella-Zoster Virus and Multiple Sclerosis
- Zoster patients: With UV 58% pain free, without UV 38% pain free - 2006
- 16X less likely to get Zoster during hemodialysis if added vitamin D drug - 2012
- Herpes Zoster Is Associated with Prior Statin Use: A Population-Based Case-Control Study
- Shingles Vaccine Shingrix approved in US - Fall 2017
- $9,520 of Shringrix to eliminate one case of Shingles (number needed to treat = 34) - April 2018
- Hypothesis and rebuttal: UV is affecting chickenpox and shingles – 2011
- Vitamin D can inhibit enveloped virus (e.g. Herpes, Zoster, Epstein, Hepatitis, Ebola) – March 2011
- The role of solar ultraviolet irradiation in zoster file, not a webpage
- Overview Pain and Vitamin D
- Virus category listing has
118 items along with related searches
- Use Google to search for (zoster OR shingles) "vitamin d" 831,000 hits as of April 2018
- Use Google to search for (zoster OR shingles) magnesium 880,000 as of April 2018
- Overview Magnesium and vitamin D
- Vitamin D can reduce the risk of Shingles Dr. Zaidi
- Prevent Herpes Outbreaks With Vitamin D HerpesBulletin 2012
- http://knowledgeofhealth.com/shingles-herpes-zoster-rates-increasing-modern-medicine-clueless-as-to-why/ Bill Sardi April 2014
50,000 IU of vitamin D and shingles pain subsides in an hour or two
VitaminDWiki suggests sublingual pill, spray, powder -Bio-Tech or topical for fast action
- Vitamin D is closely linked to the clinical courses of herpes zoster: From pathogenesis to complications
PubMed Oct 2015, Publisher wants $31 for the PDF, also available on DeepDyve
- Person applied Vitamin D directly on Shingles and also took 15,000 IU internally daily May 2016
Shingles disappeared in 3 days and pain in 5 days
- Shingles Vaccine Dangers Exposed In FDA Letter to Merck GreenMed Info May 2017
"Despite the CDC claim that the shingles vaccine carries no real risks, the FDA wrote to Merck in February 2016 telling them to add, ‘Eye Disorders: necrotizing retinitis (patients on immunosuppressive therapy)’ to their product information.' "
"With the meningitis vaccine is it worth killing three children and making 1000 more seriously ill to prevent one case of the disease?"
"Additionally, most people think that most vaccines control the spread of disease, but they don't. Many control how sick any one person gets should they come down with the disease, but the vaccine does not control the spread of that disease."
Vitamin D is closely linked to the clinical courses of herpes zoster: From pathogenesis to complications
Medical Hypothesis, Volume 85, Issue 4, Pages 452–457, October 2015
Chia-Ter Chao, Chih-Kang Chiang, Jenq-Wen Huangcorrespondenceemail, Kuan-Yu Hung
Vitamin D is renowned for its pleiotropic effects, including but not limited to bone integrity, and it has assumed an important role in the current research era. As vitamin D receptors are present in a variety of human tissues, particularly immune cells, the immunomodulatory potential of vitamin D cannot be overemphasized. Herpes zoster, which presents as grouped cutaneous vesicles over dermatomes or visceral/central nervous system infection in its severe form, has a higher incidence in immune-suppressed patients.
Considering the importance of vitamin D in host immunity, we hypothesize that vitamin D acts as an effect-modifier for the entire herpes zoster spectrum with regard to
- disease susceptibility,
- efficacy of pharmacologic management, and
- emergent complications during treatment.
Moreover, the possibility exists that vitamin D might affect the course of postherpetic neuralgia. In line with this theory, we comprehensively searched the existing herpes zoster literature and provided important insight into the relationship between the disease courses of herpes zoster and vitamin D.
Journal of Clinical Epidemiology
Volume 51, Issue 7, Pages 533-535 (July 1998)
This article is a review of the evidence suggesting a unique relationship between the varicella-zoster virus (as a possible antigen or antigen mimic) and multiple sclerosis (MS). Both MS and varicella have increased prevalences in temperate zones and both are rare in countries closer to the equator. Migration studies suggest an infectious agent acquired prior to age 14 plays a role in the risk of subsequent MS. Hutterites, who educate their children at home, have less varicella, MS, and herpes zoster than their neighbors and have the appropriate reduced varicella-zoster seropositivity matching these clinical observations. Paradoxically, patients with MS report more herpes zoster, and at an earlier age and more often, than a group of non-MS patients.
Broad-band ultraviolet B phototherapy in zoster patients may reduce the incidence and severity of postherpetic neuralgia.
Photodermatol Photoimmunol Photomed. 2006 Oct;22(5):232-7.
Jalali MH, Ansarin H, Soltani-Arabshahi R.
Department of Dermatology, Hazrat-e Rasool University Hospital, Iran University of Medical Sciences, Tehran, Iran.
BACKGROUND: Postherpetic neuralgia (PHN) is one of the common complications of herpes zoster infection, particularly in the elderly. Current therapeutic measures are only partially effective in the affected patients. As inflammatory mediators released by different cells play an important role in the pathogenesis of this neuropathic pain and with regard to the immunomodulatory effects of ultraviolet B (UVB) spectrum, we presumed that UVB phototherapy might be effective in the prevention of PHN.
METHOD: This study was performed in two phases. Phase I was a prospective open controlled trial. Twenty-five patients with severe pain in the first 7 days of zoster rash were divided into two groups: the prevention group (n=12) received oral acyclovir (800 mg five times a day for 10 days) plus broad-band UVB to the affected dermatomes, starting with 20 mJ/cm(2) and gradually increasing the dose by 10 mJ/cm(2) each session to a maximum dose of 100 mJ/cm(2). Treatment sessions were repeated three times a week until pain relief or to a maximum of 15 sessions. The control group (n=13), who had disease characteristics similar to the prevention group, received only oral acyclovir with the same dose. All patients reported their severity of pain on a verbal rating scale (VRS, score 0-4) before treatment and at 1 and 3 months' follow-up. In phase II of the study, five patients with established PHN (more than 3 months after rash onset) received UVB with the above-mentioned protocol.
RESULTS: A total of 17 patients older than 40 (10 females, seven males; mean age, 65.5 years; range: 47-82 years) who had intractable pain due to zoster infection received UVB in two phases of the study. In patients who received phototherapy in the first 7 days of rash, 58.33% and 83.33% were completely pain free at 1-and 3-month follow-up, respectively. The corresponding figure in the control group was significantly lower (38.46% at 1 month and 53.85% at 3 months). The severity of pain was also lower in the phototherapy group than the control group (mean VRS 2.50 vs. 3.28 at 3 months). None of the patients who were treated more than 3 months after rash onset (established PHN) experienced significant (more than 50%) pain relief.
CONCLUSION: UVB phototherapy in the acute stage of zoster rash might reduce the incidence and severity of PHN.
Treatment after 3 months does not seem to have a significant beneficial effect.
Risk factors for herpes zoster reactivation in maintenance hemodialysis patients
Eur J Intern Med. 2012 Sep 5.doi: 10.1016/j.ejim.2012.08.005
Chao CT, Lai CF, Huang JW.
Herpes zoster (HZ) reactivation is common in immunocompromised patients. Advanced renal failure is also reportedly associated with impairment of cellular immunity. There is not any study yet assessing risk factors of HZ reactivation in hemodialysis patients.
All patients undergoing maintenance hemodialysis for more than 3months and who developed HZ between 2000/01/01 and 2009/12/31 in a tertiary referral medical center were identified, and matched 1:1 to hemodialysis patients without HZ by age and gender.
Multivariate-adjusted conditional logistic regression model was constructed to determine possible risk factors.
Out of a total of 126 maintenance hemodialysis patients (65.3% female), 63 belonged to the HZ reactivation group and 63 to the age/sex matched control patients. Conditional logistic regression model linked corticosteroid use with heightened risk (odds ratio [OR] 20.2, 95% confidence interval [CI] 3.5-125.6; p=0.002),
while iron therapy and 1-apha-hydroxylated vitamin D were associated with significantly lower likelihood of developing HZ (OR 0.12, 95%CI 0.0-0.6; p=0.01, and OR 0.06, 95% CI 0.0-0.4; p=0.005 respectively).
CONCLUSIONS: Use of iron preparations and 1?-hydroxylated vitamin D is potentially associated with less risk of developing HZ reactivation in maintenance hemodialysis patients.
Download the PDF from VitaminDWiki
Published: October 24, 2014DOI: 10.1371/journal.pone.0111268 PLOS ONE
Shiu-Dong Chung equal contributor, Ming-Chieh Tsai equal contributor,
Shih-Ping Liu, Herng-Ching Lin, Jiunn-Horng Kang mail
Background: This study investigated the association between statin use and herpes zoster (HZ) occurrence in a population-based case-control study.
Study subjects were retrieved from the Taiwan Longitudinal Health Insurance Database 2000. This study included 47,359 cases with HZ and 142,077 controls. We performed conditional logistic regression analyses to calculate the odds ratio (OR) to present the association between HZ and having previously been prescribed statin.
We found that 13.0% of the sampled subjects had used statins, at 15.5% and 12.1% for cases and controls, respectively (p<0.001).
A conditional logistic regression analysis suggested that the adjusted OR of being a statin user before the index date for cases was 1.28 (95% confidence interval (CI): 1.24~1.32) compared to controls.
Subjects aged 18~44 years had the highest adjusted OR for prior statin use among cases compared to controls (OR: 1.69; 95% CI: 1.45~1.92).
Furthermore, we found that the ORs of being a regular and irregular statin user before the index date for cases were 1.32 (95% CI: 1.27~1.38) and 1.23 (95% CI: 1.181.29), respectively, compared to controls.
We concluded that prior statin use was associated with HZ occurrence.
Download the PDF from VitaminDWiki.
See also VitaminDWiki
No Excuses, People: Get the New Shingles Vaccine New York Times
Perhaps 90% effective for elderly
Costs over $150, Medicare will cover Shingrix under Part D
two Vaccinations needed
Remains effective ~5 years
About half of those over age 70 reported more systemic side effects like fatigue, fever or aching joints, lasting one to two days
- "Six people out of 7,344 who received the two doses of Shingrix developed shingles—that is 0.08%. 210 out of 7,415 people who received the placebo became ill with shingles—that is 3%. How do they get 98% efficacy out of these numbers? Again, I have written about how the Big Pharma Cartel manipulates statistics to make a poorly performing drug or therapy look better than it actually is by using the relative risk (RR).
- "The ARR for this study can be calculated here: 3%-0.08%=2.9%. Therefore, a more appropriate determination of the effectiveness of Shingrix is that it is 2.9% effective at preventing shingles for a median of 3.1 years (the length of the study). And, a true statement about Shingrix is that it takes 34 people to be vaccinated with Shingrix (1/2.9%) to prevent one case of shingles.
- Note: PDR listing shows Shringrix is far less efficient for those over age 80